# Atrys increased its revenue by 9.4% and its EBITDA by 21.3% in the first half of 2026

- *Atrys accelerated its growth during the half-year, with revenue growth rising from 6.3% in the first quarter to 12.3% in the second, and EBITDA growth from 15.4% to 24.1%, driven by Oncology and the strength of its international operations*

- *Revenue reached 77.7 million euros and EBITDA reached 9.3 million euros, representing growth of 9.4% and 21.3%, respectively, compared to the first half of 2025. Excluding accounting effects, EBITDA growth exceeded 44%*

- *Operating cash flow increased by 191.5% compared to the previous fiscal year, reaching 7.2 million euros, reflecting the group's improved profitability and efficiency*

- *Net financial debt fell by 79.2% following the sale of ASPY, resulting in a reduction in financial expenses of 4.4 million euros*

**SEPTEMBER 10, 2026.–** Atrys Health, a medical company specializing in the provision of healthcare services in oncology, telediagnostics, pathological anatomy, and nuclear medicine, closed the first half of 2026 with revenue of 77.7 million euros, up 9.4% from the same period the previous year. This growth was driven by the positive performance of its Oncology and Nuclear Medicine businesses, as well as by the strength of its international operations, particularly in Latin America. The company accelerated its growth rate during the half-year, with revenue growth rising from 6.3% in the first quarter to 12.3% in the second.

The positive performance of the business was also reflected in the group's key profitability indicators. EBITDA reached 9.3 million euros, representing a 21.3% increase compared to the same period last year, with growth accelerating from 15.4% in the first quarter to 24.1% in the second. Excluding accounting effects, EBITDA growth exceeded 44%. Gross profit reached 32.7 million euros, up 6.6% from the first half of 2025. This performance reflects the positive growth in business activity and the impact of the efficiency measures implemented in recent months.

Atrys also reported a significant improvement in its cash generation capacity. Operating cash flow increased by 191.5% compared to the same period last year, reaching 7.2 million euros, driven by the growth in EBITDA and the streamlining of investments, which totaled 2.1 million euros during the first half of the year.

The company also strengthened its financial structure following the sale of ASPY, which was completed in January 2026 for 145 million euros. As a result, net financial debt fell to 35.4 million euros, down 79.2% from the end of 2025. This deleveraging process led to a €4.4 million reduction in financial expenses compared to the first half of 2025. The company is also making progress in restructuring its debt to align it with the needs of its 2026–2028 Strategic Plan.

Marian Isach, CEO of Atrys, stated: "The first-half results reflect a stronger, more efficient company with a greater ability to translate growth into profitability and cash generation. The positive performance across all our geographic markets -with particularly strong results in Latin America- confirms the strength of our business model and the potential of our international strategy. Following the significant debt reduction achieved this year, we are entering a new phase with a more balanced financial structure and a focus on continuing to grow profitably in our strategic business areas".

## Strong Growth in Oncology and International Business

Oncology continued to establish itself as one of Atrys's main growth drivers during the first half of 2026. The division posted revenue of 37.1 million euros, up 22.5% from the same period last year, while its EBITDA rose 13.8% to 6 million euros. Meanwhile, Nuclear Medicine posted revenue growth of 10.6% and a strong 135.4% increase in EBITDA, driven primarily by robust performance in Portugal.

By region, Atrys has posted positive results across all its markets, with Latin America standing out for its growth (+26.1%). Mexico has been one of the main drivers, with a 151.1% increase in revenue, fueled by the consolidation of the medical oncology business and the expansion of the network of medical oncology centers.

Portugal also posted strong results during the first half of the year, with revenue up 6.7% and EBITDA 8.4 times higher than in the same period last year, thanks to the efficiency measures implemented and the strong growth in the Nuclear Medicine segment.

In Spain, business continued to trend upward, with revenue increasing by 1.3%, driven by strong performance in Diagnostic Imaging (+18.2%) and Oncology (+5.7%).

This performance is part of the implementation of Atrys' new organizational model in 2026, aimed at strengthening the group's operational efficiency, management discipline, and profitability.

## Atrys reaffirms its 2026 Guidance

Following its first-half results, Atrys reaffirms its forecasts for 2026 as a whole, which call for revenue of 156.5 million euros (+11%); reported EBITDA of 20.5 million (+40%); and operating cash flow of 13.5 million euros, up 125% from the previous year.

Today, Thursday, September 10, at 10:00 a.m., Atrys will hold a webcast to present its results for the first half of 2026. To register for online access, please use this link: https://streamstudio.world-television.com/CCUIv3/registration.aspx?ticket=1445-2730-43643&target=es-default-&status=preview&browser=ns-0-1-0-0-0

## About Atrys

Atrys is a medical company operating in seven countries that specializes in providing healthcare services in oncology, telediagnostics, pathological anatomy, and nuclear medicine, and offers its clients clinical solutions designed to improve care and address long-term structural challenges.

## Media contacts

Diana Barriga
Atrys
dbarriga@atryshealth.com
+34 649 042 525

Marta Estarellas
Roman
m.estarellas@romanrmcom
+34 663 027 941